Cargando…
m(6)A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer
OBJECTIVE: Pancreatic cancer is one of the most lethal human malignancies. Gemcitabine is widely used to treat pancreatic cancer, and the resistance to chemotherapy is the major difficulty in treating the disease. N (6)-methyladenosine (m(6)A) modification, which regulates RNA splicing, stability, t...
Autores principales: | Zhang, Congjun, Ou, Shuangyan, Zhou, Yuan, Liu, Pei, Zhang, Peiying, Li, Ziqian, Xu, Ruocai, Li, Yuqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385558/ https://www.ncbi.nlm.nih.gov/pubmed/34458141 http://dx.doi.org/10.3389/fonc.2021.696371 |
Ejemplares similares
-
Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase
por: Amit, Moran, et al.
Publicado: (2013) -
Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019) -
Roles of the m6A methyltransferases METTL3, METTL14, and WTAP in pulmonary tuberculosis
por: Zhang, Tian-Ping, et al.
Publicado: (2022) -
Deaminase-Independent Inhibition of Parvoviruses by the APOBEC3A Cytidine Deaminase
por: Narvaiza, Iñigo, et al.
Publicado: (2009) -
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients
por: Serdjebi, Cindy, et al.
Publicado: (2015)